- Funding Received
- $2.6 Million in 1 Round from 1 Investor
- Most Recent Funding
- $2.6 Million on January 14, 2009 / Undisclosed Round
- OY LX Therapies is focused on developing gene-mediated therapies for the prevention and treatment of diseases of lymphatic vasculature.
Lx Therapies, founded in 2008, is a drug discovery company focused on developing genemediated therapies for the prevention and treatment of diseases of lymphatic vasculature. The initial focus of the company is on breast cancer-related lymphoedema, a relatively common complication of breast cancer treatment for which there is currently no cure or effective treatment. Lx Therapies, based in Helsinki, has received a EUR 2 million investment from Inveni Capital, the Finnish-German life sciences venture fund and a founder of Lx Therapies.